Captrust Financial Advisors Anavex Life Sciences Corp. Transaction History

Captrust Financial Advisors

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$9.74 - $17.69 $224 - $406	-23 Reduced 2.25%	1,000 $12,000
Q4 2021 Feb 14, 2022	BUY	$16.88 - $23.31 $388 - $536	23 Added 2.3%	1,023 $18,000
Q3 2021 Nov 16, 2021	SELL	$16.82 - $25.75 $7,182 - $10,995	-427 Reduced 29.92%	1,000 $18,000
Q2 2021 Aug 16, 2021	SELL	$10.16 - $28.86 $20,492 - $58,210	-2,017 Reduced 58.57%	1,427 $33,000
Q1 2021 May 17, 2021	BUY	$5.17 - $16.13 $10,050 - $31,356	1,944 Added 129.6%	3,444 $51,000
Q2 2020 Aug 14, 2020	BUY	$2.62 - $5.2 $3,930 - $7,800	1,500 New	1,500 $8,000

188

29.2M

894K

821K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $726M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.